UCSD Cancer Center Training Program in Drug Development

加州大学圣地亚哥分校癌症中心药物开发培训项目

• 批准号: 10411844
• 负责人: Michael Bouvet
• 金额: $ 63.71万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10411844
• 关键词: Cancer Center; Training Programs; drug development

PROJECT SUMMARY/ABSTRACT This renewal application seeks funding to continue the highly successful Cancer Therapeutics Training (CT2) Program at the Moores Comprehensive Cancer Center at the University of California, San Diego. About 40% of Americans will develop cancer in their lifetime. More than 600,000 fall to cancer each year. The mission of the CT2 program is to train PhD and MD-physician-scientists who will become the next generation of leaders in the field of cancer drug and therapeutics in each of the major steps required for successful translation of laboratory- based discoveries into safe and effective therapeutic agents. The CT2 training is designed to position trainees to play key leadership roles in the field of oncology therapeutics. The 31 faculty of the CT2 Program are all Members of the Cancer Center and are appointed in 11 departments in the School of Medicine, the Skaggs School of Pharmacy and Pharmaceutical Sciences or the general campus. Each faculty preceptor is an accomplished investigator and educator with a history of training superb postdoctoral fellows. Each has substantial peer-reviewed cancer or cancer-related research funding. All of the participating faculty are conducting translational research and have been selected because of their interest in new cancer therapeutics. This program is extensively integrated with other activities of the UC San Diego Moores Cancer Center and the extensive biotech/pharma industry in San Diego. The goal is to recruit and retain 8 MD and PhD scientists in this two-year program that will position them for careers in the development of new cancer drugs or the diagnostics needed to guide the use of these drugs in the era of personalized medicine. The training program components include: the completion of formal didactic teaching sessions that cover tools essential to the drug development process; the conduct of one or more steps in therapeutic development research project under the direction of a faculty preceptor; and required participation in individual development plans, including yearly attendance at the annual meeting of the American Association for Cancer Research or an equivalent national meeting. Trainees are also expected to participate in Cancer Center and Departmental seminars, research rounds, and journal clubs to expand the breadth of their understanding of cancer research and prepare formal project plans and practice or real grant applications for review by the Executive Committee. Methods are in place to ensure that all trainees are properly instructed in the principles of responsible conduct of research and scientific integrity. Trainees are recruited nationwide and special efforts are made recruit and retain exceptional candidates from groups historically underrepresented in biomedical sciences.

项目摘要/摘要 该更新应用程序寻求资金继续进行非常成功的癌症治疗培训（CT2） 在加利福尼亚大学圣地亚哥分校的摩尔综合癌症中心计划。约40％ 美国人一生将发展癌症。每年有超过60万次癌症。任务 CT2计划将培训博士学位和MD-Physician-Scientist，他们将成为下一代领导者 在成功翻译实验室所需的每个主要步骤中，癌症药物和治疗剂领域 基于安全有效的治疗剂的发现。 CT2培训旨在定位受训者 在肿瘤学治疗领域中扮演关键的领导角色。 CT2计划的31位教职员工都是 癌症中心的成员，被任命在医学院的11个部门，Skaggs 药学和药学学院或一般校园。每个教师主持人都是 有成就的调查员和教育家拥有培训精湛博士后研究员的历史。每个都有 大量同行评审的癌症或与癌症有关的研究资金。所有参与的教师都是 进行翻译研究并因其对新的癌症治疗剂的兴趣而被选中。 该计划与加州大学圣地亚哥摩尔分校癌症中心的其他活动和 圣地亚哥广泛的生物技术/制药行业。目标是在 这个为期两年的计划将使他们从事新的癌症药物的职业或 在个性化医学时代，需要指导这些药物使用这些药物。培训计划 组件包括：正式教学教学课程的完成，涵盖对药物必不可少的工具 发展过程；在治疗发展研究项目中的一个或多个步骤 教师主持人的方向；并需要参与个人发展计划，包括年度 参加美国癌症研究协会年会或同等国家会议 会议。预计学员还将参加癌症​​中心和部门研讨会，研究 回合和期刊俱乐部，以扩大他们对癌症研究的理解的广度并准备正式 执行委员会的项目计划和实践或实际赠款申请进行审查。方法已经到位 确保所有受训人员都得到负责任的研究原则的适当指导和 科学完整性。在全国范围内招募了学员，并进行特殊努力，并保留了杰出的 从历史上讲，来自生物医学科学的人数不足。